BE2016C051I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C051I2
BE2016C051I2 BE2016C051C BE2016C051C BE2016C051I2 BE 2016C051 I2 BE2016C051 I2 BE 2016C051I2 BE 2016C051 C BE2016C051 C BE 2016C051C BE 2016C051 C BE2016C051 C BE 2016C051C BE 2016C051 I2 BE2016C051 I2 BE 2016C051I2
Authority
BE
Belgium
Application number
BE2016C051C
Other languages
French (fr)
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18978246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C051(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of BE2016C051I2 publication Critical patent/BE2016C051I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BE2016C051C 2001-04-26 2016-11-03 BE2016C051I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001129765 2001-04-26
PCT/JP2002/004118 WO2002088084A1 (en) 2001-04-26 2002-04-25 Heterocyclic compound derivatives and medicines

Publications (1)

Publication Number Publication Date
BE2016C051I2 true BE2016C051I2 (en) 2021-07-19

Family

ID=18978246

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C051C BE2016C051I2 (en) 2001-04-26 2016-11-03

Country Status (19)

Country Link
US (1) US7205302B2 (en)
EP (1) EP1400518B1 (en)
JP (1) JP4479152B2 (en)
KR (1) KR100921760B1 (en)
CN (1) CN1301973C (en)
BE (1) BE2016C051I2 (en)
BR (1) BRPI0209249B8 (en)
CA (1) CA2445344C (en)
DE (1) DE60217674T2 (en)
DK (1) DK1400518T3 (en)
ES (1) ES2276931T3 (en)
FR (1) FR16C0042I2 (en)
LU (1) LU93266I2 (en)
MX (1) MXPA03009800A (en)
NL (1) NL300836I2 (en)
PT (1) PT1400518E (en)
RU (1) RU2283835C3 (en)
TW (1) TWI316055B (en)
WO (1) WO2002088084A1 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
FR2869224B1 (en) * 2004-04-22 2006-06-09 Oreal 2-OXY-ACETAMIDE COMPOUND, USES THEREOF AND COMPOSITIONS FOR STIMULATING OR INDUCING THE PUSH OF KERATIN FIBERS AND / OR BRAKING THEIR FALL
EP1763382A1 (en) * 2004-04-22 2007-03-21 L'oreal 2-oxy-acetamide compound, the uses thereof and compositions for stimulating or inducing the growth, and/or retarding the loss, of keratin fibres
AR053712A1 (en) * 2005-04-18 2007-05-16 Neurogen Corp HETEROARILOS SUBSTITUTED, ANTAGONISTS OF CB1 (RECEIVER 1 CANABINOID)
LT2246336T (en) 2008-02-28 2020-08-25 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
AU2009226151B2 (en) * 2008-03-18 2013-10-31 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
WO2009154246A1 (en) * 2008-06-19 2009-12-23 日本新薬株式会社 Therapeutic agent for erectile dysfunction
US8394793B2 (en) * 2008-06-23 2013-03-12 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
WO2009157397A1 (en) * 2008-06-23 2009-12-30 日本新薬株式会社 Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid anti-inflammatory agent
HUE025885T2 (en) * 2008-06-23 2016-05-30 Nippon Shinyaku Co Ltd Therapeutic agent for spinal canal stenosis
MY163762A (en) * 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
EP3300729B1 (en) * 2008-08-13 2019-10-09 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan
MX2011013471A (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals.
WO2011024874A1 (en) * 2009-08-26 2011-03-03 日本新薬株式会社 Base addition salts
ES2525748T3 (en) 2009-11-13 2014-12-29 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes
EP2531492B1 (en) 2010-02-05 2016-04-13 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
KR101491938B1 (en) 2010-07-14 2015-02-10 노파르티스 아게 Ip receptor agonist heterocyclic compounds
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2816023A4 (en) 2012-02-13 2015-09-09 Takeda Pharmaceutical Aromatic ring compound
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical Aromatic ring compound
JP6400479B2 (en) 2012-10-29 2018-10-03 株式会社カルディオ Lung disease specific therapeutic agent
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
CN103588598B (en) * 2013-11-20 2015-06-17 苏州大学 Method for preparing 2-olefine aldehyde derivatives
CN104829465B (en) 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 A kind of preparation method of 4- isopropylaminos-n-butyl alcohol
CN106279047B (en) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 A kind of preparation method of prostacyclin receptor agonist
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
CN106467496B (en) * 2015-08-14 2020-12-08 苏州国匡医药科技有限公司 Preparation method of 4- [ (5, 6-diphenyl piperazine-2-yl) (isopropyl) amino ] -1-butanol
US10188648B2 (en) 2015-09-03 2019-01-29 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042828A2 (en) 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017060827A1 (en) 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
JP6825574B2 (en) * 2015-12-02 2021-02-03 日本新薬株式会社 A pharmaceutical composition containing 2- {4- [N- (5,6-diphenylpyrazine-2-yl) -N-isopropylamino] butyloxy} -N- (methylsulfonyl) acetamide.
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
JP7149073B2 (en) * 2015-12-23 2022-10-06 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Compound
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
ES2911531T3 (en) 2016-04-01 2022-05-19 Honour R&D Procedure for the preparation of diphenylpyrazine derivatives
CN107286104A (en) * 2016-04-12 2017-10-24 常州方楠医药技术有限公司 A kind of Sai Lexipa and pharmaceutic adjuvant solid dispersions and preparation method thereof
CN105949135A (en) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 Synthetic method of selexipag
CA3029960A1 (en) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018015975A1 (en) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018019296A1 (en) * 2016-07-29 2018-02-01 成都苑东生物制药股份有限公司 Aminopyrazine compound, salt, or isomer, preparation method therefor, and application thereof
BR112018076800A2 (en) 2016-07-29 2019-04-02 Toray Industries, Inc. guanidine derivative, medicament, protein 1 inhibitor of mucosal-associated lymphoid tissue lymphoma translocation, and therapeutic or prophylactic agent.
CN106316967B (en) * 2016-08-19 2019-02-05 上海艾康睿医药科技有限公司 The preparation method of West pa lattice intermediate and West pa lattice
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
WO2018112258A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
JOP20190204A1 (en) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
CN107365275B (en) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 High purity celecoxib
US20200171026A1 (en) 2017-07-27 2020-06-04 Allergan, Inc. Prostacyclin receptor agonists for reduction of body fat
TWI834536B (en) 2017-09-28 2024-03-01 日商日本新藥股份有限公司 Crystals
AR113882A1 (en) 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd CONTROLLED RELEASE PREPARATION
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
CN111699175B (en) * 2018-02-07 2022-03-29 南京明德新药研发有限公司 Prostacyclin receptor agonists
PE20210448A1 (en) 2018-02-21 2021-03-08 Nippon Shinyaku Co Ltd GRANULAR COMPOSITION, PRODUCTION METHOD FOR GRANULAR COMPOSITION AND DISSOLUTION PROPERTY IMPROVEMENT METHOD FOR GRANULAR COMPOSITION
CN108558653A (en) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 The preparation method of Sai Lexipa intermediates and Sai Lexipa
CN108863955B (en) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 Diphenyl pyrazine compound or pharmaceutically acceptable salt and isomer thereof, and preparation method and application thereof
CN108774183A (en) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 A kind of preparation method of ethylene glycol compounds
CN109125325B (en) * 2018-09-25 2021-05-25 中国人民解放军总医院 Medical application of prostacyclin receptor agonist
WO2020225297A1 (en) 2019-05-06 2020-11-12 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
EP3972602A2 (en) 2019-05-21 2022-03-30 Actelion Pharmaceuticals Ltd Transitioning patients treated for pulmonary arterial hypertension to selexipag
US20220323437A1 (en) 2019-06-11 2022-10-13 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
KR20220049565A (en) * 2019-08-19 2022-04-21 니뽄 신야쿠 가부시키가이샤 salt
US20220401441A1 (en) 2019-10-23 2022-12-22 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
MX2022006403A (en) 2019-11-29 2022-08-25 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension.
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
JP2023512266A (en) 2020-02-03 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド Methods of treating and evaluating pulmonary arterial hypertension with selexipag
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202241425A (en) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 Process for manufacturing a diphenylpyrazine derivative
TW202239408A (en) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative
CN117157075A (en) 2021-03-31 2023-12-01 日本新药株式会社 Remedies for gait disorder
JP7010404B1 (en) 2021-03-31 2022-02-10 日本新薬株式会社 Gait disorder treatment agent
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
CN118146165A (en) * 2021-11-29 2024-06-07 郑州大学 2,3, 5-Trisubstituted pyrazine compound and preparation method and application thereof
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
TW202426428A (en) * 2022-12-20 2024-07-01 大陸商長風藥業股份有限公司 Diphenyl pyrazine derivative, preparation method therefor, and use thereof
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1604084A (en) 1977-05-17 1981-12-02 Diamond Shamrock Corp Pharmaceutical preparations containing 1,2,4-triazine derivatives
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FR2665159B1 (en) * 1990-07-24 1992-11-13 Rhone Poulenc Sante NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH06501926A (en) 1990-08-06 1994-03-03 藤沢薬品工業株式会社 heterocyclic compound
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JP3169413B2 (en) * 1992-01-31 2001-05-28 エーザイ株式会社 Imidazole derivatives
JPH0733752A (en) 1993-07-16 1995-02-03 Sankyo Co Ltd Diphenylpyrazine derivative and herbicide
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist

Also Published As

Publication number Publication date
BR0209249A (en) 2004-06-08
KR100921760B1 (en) 2009-10-15
RU2283835C2 (en) 2006-09-20
EP1400518A1 (en) 2004-03-24
FR16C0042I2 (en) 2017-03-17
LU93266I2 (en) 2016-12-19
CN1516690A (en) 2004-07-28
KR20040015174A (en) 2004-02-18
US20040102436A1 (en) 2004-05-27
CA2445344A1 (en) 2002-11-07
RU2283835C3 (en) 2021-02-15
CN1301973C (en) 2007-02-28
TWI316055B (en) 2009-10-21
FR16C0042I1 (en) 2016-12-09
NL300836I2 (en) 2016-11-16
EP1400518A4 (en) 2005-04-20
MXPA03009800A (en) 2004-01-29
CA2445344C (en) 2011-07-26
DE60217674D1 (en) 2007-03-08
JPWO2002088084A1 (en) 2004-09-09
ES2276931T3 (en) 2007-07-01
WO2002088084A1 (en) 2002-11-07
DK1400518T3 (en) 2007-03-26
EP1400518B1 (en) 2007-01-17
PT1400518E (en) 2007-03-30
JP4479152B2 (en) 2010-06-09
RU2003134190A (en) 2005-06-10
BRPI0209249B8 (en) 2021-05-25
US7205302B2 (en) 2007-04-17
DE60217674T2 (en) 2007-10-11
BRPI0209249B1 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en)
BE2022C547I2 (en)
BE2017C056I2 (en)
BE2016C051I2 (en)
BE2015C077I2 (en)
BE2014C052I2 (en)
FR14C0033I1 (en)
BE2011C034I2 (en)
BE2007C047I2 (en)
AU2002307149A8 (en)
JP2002115847A5 (en)
JP2002217377A5 (en)
BRPI0209186B1 (en)
BRPI0204884A2 (en)
CH1379220H1 (en)
BE2017C059I2 (en)
DE60143321D1 (en)
JP2002217943A5 (en)
JP2002195419A5 (en)
BRPI0210463A2 (en)
JP2002029229A5 (en)
AU2000280389A8 (en)
JP2002123190A5 (en)
JP2002207106A5 (en)
JP2002252352A5 (en)